IP Library › Granted Patent US 7,462,643
Granted Patent B1
US 7,462,643 · App. 09/869,333 · Granted Dec 9, 2008

Essential fatty acids in the prevention of cardiovascular events

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,462,643
App. No.
09/869,333
Granted
Dec 9, 2008
Kind
B1
Abstract

The invention concerns the use of essential fatty acids with a high content in eicosapentaenoic acid ethyl ester (EPA) or docosahexaenoic acid ethyl ester (DHA) or a high concentration mixture thereof in the preparation of a medicament useful for preventing mortality, in particular due to sudden death, in patients who have suffered from a myocardial infarction.

Claims (26)

1. A method of reducing the incidence of mortality caused by the reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the mixture is from about 60 to about 100% by weight, and wherein the medicament is administered orally at an essential fatty acids dosage of from about 0.7 g to about 1.5 g daily.

2. The method according to claim 1 , wherein the content of EPA+DHA in the mixture is about 85% by weight.

3. The method according to claim 1 , wherein the medicament is administered orally at an essential fatty acids dosage of about 1 g daily.

4. The method according to claim 1 , wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

5. The method according to claim 1 , wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 50% by weight.

6. The method according to claim 1 , wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

7. A method of reducing the incidence of sudden death caused by the reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, comprising administering to said patient a therapeutically effective amount of a medicament containing essential fatty acids containing a mixture of eicosapentaenoic acid ethyl ester (EPA) and docosahexaenoic acid ethyl ester (DHA) wherein the content of EPA+DHA in the mixture is from about 60 to about 100% by weight, and wherein the medicament is administered orally at an essential fatty acids dosage of from about 0.7 g to about 1.5 g daily.

8. The method according to claim 7 , wherein the content of EPA+DHA in the mixture is about 85% by weight.

9. The method according to claim 7 , wherein the medicament is administered orally at an essential fatty acids dosage of about 1 g daily.

10. The method according to claim 7 , wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

11. The method according to claim 7 , wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 50% by weight.

12. The method according to claim 7 , wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

13. A method of reducing the incidence of mortality caused by the reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, comprising administering to said patient oral dosage forms comprising 1 g of oil containing ethyl esters of polyunsaturated fatty acids comprising omega-3 fatty acids comprising a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the content of EPA+DHA in the oil is from about 60 to about 100% by weight, in an amount effective to reduce the incidence of mortality in the patient.

14. The method according to claim 13 , wherein the content of EPA+DHA in the oil is about 85% by weight.

15. The method according to claim 13 , wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

16. The method according to claim 13 , wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 50% by weight.

17. The method according to claim 13 , wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

18. A method of reducing the incidence of sudden death caused by the reoccurrence of cardiovascular events in a patient who has survived a myocardial infarction, comprising administering to said patient oral dosage forms comprising 1 g of oil containing ethyl esters of polyunsaturated fatty acids comprising omega-3 fatty acids comprising a mixture of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) wherein the content of EPA+DHA in the oil is from about 60 to about 100% by weight, in an amount effective to reduce the incidence of sudden death in the patient.

19. The method according to claim 18 , wherein the content of EPA+DHA in the oil is about 85% by weight.

20. The method according to claim 18 , wherein the content of EPA in the EPA+DHA mixture is from about 40 to about 60% by weight.

21. The method according to claim 18 , wherein the content of DHA in the EPA+DHA mixture is from about 25 to about 50% by weight.

22. The method according to claim 18 , wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

23. The method of claim 1 , wherein the content of EPA+DHA in the mixture is about 85% by weight; wherein the medicament is administered orally at an essential fatty acids dosage of about 1g daily; and wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

24. The method of claim 7 , wherein the content of EPA+DHA in the mixture is about 85% by weight; wherein the medicament is administered orally at an essential fatty acids dosage of about 1 g daily; and wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

25. The method of claim 13 , wherein the content of EPA+DHA in the mixture is about 85% by weight, and wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.

26. The method of claim 18 , wherein the content of EPA+DHA in the mixture is about 85% by weight, and wherein the EPA content of the EPA+DHA mixture is from about 40 to about 60% by weight and the DHA content of the EPA+DHA mixture is from about 25 to about 50% by weight.